The independent company being created by a joint venture between Israel’s Teva Pharmaceutical Industries ($TEVA) and Japan’s Takeda Pharmaceutical became a bit more clear this week when the two pharma giants released additional details on their plans.
The companies said the products being shifted to the new company will include Blopress for hypertension, Takepron for peptic ulcers, and Basen for Type 2 diabetes. Sales revenue generated by those drugs totaled ¥125 billion ($1.03 billion) in fiscal 2014, which was 7% of Takeda’s total global revenue, according to a statement released by the two firms. The two also said the drug Leuplin will remain a part of Takeda in its oncology unit.
The companies said in the statement that Takeda’s overall revenue is expected to decline by ¥50 billion yen as a result of the deal.
Teva and Takeda said the new company, which will be majority owned by Teva, will be made up of Teva Takeda Pharma and Teva Takeda Yakuhin. The companies said the deal should be “EPS and cash flow accretive” in fiscal 2016 and that long-term growth in its generic business will also be positive.
Takeda’s hiving off of some of its no-growth drugs into the new company is an effort to focus on more financially rewarding new drugs, but the market for off-patent drugs and generics in Japan is expected to remain strong for the new company, because the country, like others in Asia, is trying to cut its national healthcare spending and rely more on such medicines.
By Matthew Driskill
Source: Fierce Pharma Asia
The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.
Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.
Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.